The cost of We­govy: $1.1M to pre­vent one ma­jor car­dio­vas­cu­lar event, Airfin­i­ty says

The im­pact of No­vo Nordisk’s GLP-1 semaglu­tide on car­dio­vas­cu­lar health was re­ceived with great fan­fare ear­li­er this month, with the Dan­ish phar­ma tout­ing a 20 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER